Abstract

SGLT INHIBITORS AS AN ANTIDIABETEC AGENTS

Ayodhya Tanaji Pardhe*, Shubhangi Manikpuriya, Dr. Gajanan Sanap and Pooja Dhamale

.

Abstract

Diabetes Mellitus is the most common metabolic disorders that substantially contributes to increase in global health burden. DM is associated with various medical conditions, diseases such as hypertension, obesity, cardiovascular diseases and atherosclerosis. Diabetes mellitus classified in major 3 types that are Type1 DM, Type 2 DM and gestational diabetes. There are various classes of drugs which are used in the treatment or control the DM such as Insulin, Biguanides, Sulfonylureas, Metformin, DPP4 inhibitors, GLP-1 inhibitors and SGLT2 inhibitors. In this review, cover the study of diabetes mellitus with their type, anti-diabetes drugs, and main focus on the sodium/glucose co-transporter [SGLT2] inhibitors. Sodium/glucose co-transporters [SGLT] are large of the proteins that improve the transport of sugars like fructose, fructose, galactose and also transport the sodium across the plasma membrane of cell from variety of tissues. SGLT receptors are promoted the reabsorption of glucose in the kidney. The inhibition of the SGLT2 inhibitors decreases the reabsorption of glucose and increases the excretion of glucose through the urine. There are various types of FDA approved drugs that are Canagliflozin, Dapagliflozin, Empagliflozin which are used in the management or control the diabetes mellitus.

Keywords: Diabetes Mellitus, Oral Antidiabetic Agents, Sodium Glucose Co- Transporter Inhibitors 2 (SGLTI2).